Coriolis Pharma Excels with TOP10 Listed Articles in JPharmSci


Scientific excellence in biopharmaceutical contract research for protein formulation development, aggregation analysis and particle characterization

Martinsried/Munich, Germany, June 5, 2012 / B3C newswire / - Coriolis Pharma staff and scientific advisory board members are pleased to announce that they hold three positions in the JPharmSci TOP10 of most downloaded publications.

“Such a triple is the first time ever in the Journal’s history and we feel very pleased about this appreciation of our scientific activities. Moreover, the high interest from researchers all over the world in downloading our papers give us the confidence to continue operating at the cutting edge in this field and sharing our knowledge with the scientific community and our customers”, states Dr. Michael Wiggenhorn, CEO of Coriolis Pharma.

JPharmSci allows free download of the TOP10 papers until end of June including three papers with involvement from Coriolis Pharma:

Forced degradation of therapeutic proteins
Andrea Hawe, Michael Wiggenhorn, Marco van de Weert, Joerg H. O. Garbe, Hanns-Christian Mahler, Wim Jiskoot

Particles in therapeutic protein formulations, Part 1: Overview of analytical methods
Sarah Zölls, Ruedeeporn Tantipolphan, Michael Wiggenhorn, Gerhard Winter, Wim Jiskoot, Wolfgang Friess, Andrea Hawe

Protein instability and immunogenicity: Roadblocks to clinical application of injectable protein delivery systems for sustained release
Wim Jiskoot, Theodore W. Randolph, David B. Volkin, C. Russell Middaugh, Christian Schöneich, Gerhard Winter, Wolfgang Friess, Daan J. A. Crommelin, John F. Carpenter

More highly relevant publications from Coriolis Pharma related to protein aggregation analysis, particle characterization and formulation development for biopharmaceuticals can be found on


About Coriolis Pharma
Coriolis Pharma is a globally operating independent service provider for research and development of (bio)pharmaceutical drugs (proteins, peptides, monoclonal antibodies, RNA/DNA etc.) and vaccines.

An interdisciplinary team of highly qualified scientists with many years of experience in the development of (bio)pharmaceuticals supported by an expert scientific advisory board provides cutting-edge service and know-how related to the formulation development of biopharmaceuticals.

This may involve for example formulation development of (pre-)clinical material through to commercial products, lyophilization processes, stability testing (light obscuration, Micro-Flow Imaging and AF4/HF5 under cGMP), supply of pre-clinical material, and innovative analytical technologies for aggregate analysis and particle characterization.


Dr. Michael Wiggenhorn, CEO
Coriolis Pharma
Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 – 5 42 44 98-0
This email address is being protected from spambots. You need JavaScript enabled to view it.

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.